Venture Capital Trusts: The Maven VCTs explained

As we start a new year, the attention for many investors starts to shift towards April and planning for the end of the tax year. The Venture Capital Trust fundraising season is now in full flow and Wealth Club recently interviewed Bill Nixon to provide further insight for prospective investors who are considering investment into a VCT this year.

VCT investments are not suitable for every investor, as they require more advanced knowledge and risk appetite. Any decision to invest should only be made on the basis of information contained in the Prospectus for the Offers which can be found here: mavencp.com/vctoffer

This interview covers:

• What we consider are the sectors that offer the best prospect of significant capital gain?
• Which sectors do we avoid and why?
• Our recent investments in Manufacture 2030 (carbon emissions tracking), iAM Compliant (education compliance), Laverock Therapeutics (cell and gene therapies) and Oxford BioDynamics Plc (diagnostics technology).
• The progress of established Maven VCT portfolio companies Summize (AI-powered legal software), XR Games (virtual reality video games) and Bright Network (graduate recruitment platform).
• How our support for companies goes far beyond just providing capital.
• Recent exits in the VCT portfolio including Quorum Cyber and e.fundamentals.
• Performance and dividends.
  
  
  

Watch the video in full below:

Target Market 
VCTs are intended for UK taxpayers aged 18 or over with an investment horizon of five or more years and who are able to bear up to 100% capital loss and with a medium to high risk tolerance. Investors in the VCT will generally be informed investors with either experience in investing in VCTs or with a knowledge and understanding of the risks involved.